CN109432243A - A kind of resveratrol process for preparing buccal lozenge - Google Patents
A kind of resveratrol process for preparing buccal lozenge Download PDFInfo
- Publication number
- CN109432243A CN109432243A CN201811548829.XA CN201811548829A CN109432243A CN 109432243 A CN109432243 A CN 109432243A CN 201811548829 A CN201811548829 A CN 201811548829A CN 109432243 A CN109432243 A CN 109432243A
- Authority
- CN
- China
- Prior art keywords
- resveratrol
- lozenge
- preparing buccal
- vitamin
- buccal lozenge
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 title claims abstract description 66
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 title claims abstract description 66
- 235000021283 resveratrol Nutrition 0.000 title claims abstract description 66
- 229940016667 resveratrol Drugs 0.000 title claims abstract description 66
- 239000007937 lozenge Substances 0.000 title claims abstract description 34
- 238000004519 manufacturing process Methods 0.000 title claims description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 40
- 239000000284 extract Substances 0.000 claims abstract description 15
- 238000002360 preparation method Methods 0.000 claims abstract description 12
- 239000004383 Steviol glycoside Substances 0.000 claims abstract description 10
- 235000009754 Vitis X bourquina Nutrition 0.000 claims abstract description 10
- 235000012333 Vitis X labruscana Nutrition 0.000 claims abstract description 10
- 235000014787 Vitis vinifera Nutrition 0.000 claims abstract description 10
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims abstract description 10
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229930182488 steviol glycoside Natural products 0.000 claims abstract description 10
- 235000019411 steviol glycoside Nutrition 0.000 claims abstract description 10
- 150000008144 steviol glycosides Chemical class 0.000 claims abstract description 10
- 235000019202 steviosides Nutrition 0.000 claims abstract description 10
- 235000010447 xylitol Nutrition 0.000 claims abstract description 10
- 239000000811 xylitol Substances 0.000 claims abstract description 10
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims abstract description 10
- 229960002675 xylitol Drugs 0.000 claims abstract description 10
- 239000000706 filtrate Substances 0.000 claims abstract description 9
- 238000000034 method Methods 0.000 claims abstract description 9
- 229930003231 vitamin Natural products 0.000 claims abstract description 7
- 235000013343 vitamin Nutrition 0.000 claims abstract description 7
- 239000011782 vitamin Substances 0.000 claims abstract description 7
- 229940088594 vitamin Drugs 0.000 claims abstract description 7
- 238000000120 microwave digestion Methods 0.000 claims abstract description 6
- 150000003722 vitamin derivatives Chemical class 0.000 claims abstract description 6
- STLFUWRAUIJKJC-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;zinc Chemical compound [Zn].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O STLFUWRAUIJKJC-BTVCFUMJSA-N 0.000 claims abstract description 3
- 240000006365 Vitis vinifera Species 0.000 claims abstract 2
- 235000019441 ethanol Nutrition 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 10
- 235000013305 food Nutrition 0.000 claims description 8
- 229920002472 Starch Polymers 0.000 claims description 7
- 239000008107 starch Substances 0.000 claims description 7
- 235000019698 starch Nutrition 0.000 claims description 7
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 claims description 6
- 239000003480 eluent Substances 0.000 claims description 6
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 4
- 229910052782 aluminium Inorganic materials 0.000 claims description 4
- 239000004411 aluminium Substances 0.000 claims description 4
- 238000004458 analytical method Methods 0.000 claims description 4
- 238000002386 leaching Methods 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 238000004587 chromatography analysis Methods 0.000 claims 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 10
- 241000219095 Vitis Species 0.000 description 9
- 238000000605 extraction Methods 0.000 description 7
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 5
- 241000205407 Polygonum Species 0.000 description 5
- 229930003451 Vitamin B1 Natural products 0.000 description 5
- 229930003268 Vitamin C Natural products 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 229960003495 thiamine Drugs 0.000 description 5
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 5
- 235000010374 vitamin B1 Nutrition 0.000 description 5
- 239000011691 vitamin B1 Substances 0.000 description 5
- 235000019154 vitamin C Nutrition 0.000 description 5
- 239000011718 vitamin C Substances 0.000 description 5
- 229960000306 zinc gluconate Drugs 0.000 description 5
- 235000011478 zinc gluconate Nutrition 0.000 description 5
- 239000011670 zinc gluconate Substances 0.000 description 5
- 241000489523 Veratrum Species 0.000 description 4
- 239000003826 tablet Substances 0.000 description 3
- 244000037364 Cinnamomum aromaticum Species 0.000 description 2
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 229930182478 glucoside Natural products 0.000 description 2
- 150000008131 glucosides Chemical class 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- 241000563984 Ampelopsis Species 0.000 description 1
- 235000003911 Arachis Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- PYIXHKGTJKCVBJ-UHFFFAOYSA-N Astraciceran Natural products C1OC2=CC(O)=CC=C2CC1C1=CC(OCO2)=C2C=C1OC PYIXHKGTJKCVBJ-UHFFFAOYSA-N 0.000 description 1
- NDVRQFZUJRMKKP-UHFFFAOYSA-N Betavulgarin Natural products O=C1C=2C(OC)=C3OCOC3=CC=2OC=C1C1=CC=CC=C1O NDVRQFZUJRMKKP-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 244000166124 Eucalyptus globulus Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 235000009388 Parthenocissus quinquefolia Nutrition 0.000 description 1
- IHPVFYLOGNNZLA-UHFFFAOYSA-N Phytoalexin Natural products COC1=CC=CC=C1C1OC(C=C2C(OCO2)=C2OC)=C2C(=O)C1 IHPVFYLOGNNZLA-UHFFFAOYSA-N 0.000 description 1
- 241000219050 Polygonaceae Species 0.000 description 1
- 241000219784 Sophora Species 0.000 description 1
- 241000219094 Vitaceae Species 0.000 description 1
- 235000009392 Vitis Nutrition 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 235000001497 healthy food Nutrition 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000280 phytoalexin Substances 0.000 description 1
- 150000001857 phytoalexin derivatives Chemical class 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- -1 polyphenol compound Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229910052573 porcelain Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229940057613 veratrum Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Botany (AREA)
- Heart & Thoracic Surgery (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Alternative & Traditional Medicine (AREA)
- Inorganic Chemistry (AREA)
- Biotechnology (AREA)
- Physiology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses a kind of resveratrol lozenges and preparation method thereof, it is mixed by grape skin with ethanol solution, at 50 DEG C twice using microwave digestion, 0.05h is extracted every time, is filtered after impregnating 30min, it is chromatographed after filtrate twice is merged, resveratrol extract is prepared, this method can shorten resveratrol preparation time, while can improve the content of resveratrol in resveratrol extract, it can reach 10% or more, and then the higher resveratrol lozenge of levels can be prepared.And lozenge mouthfeel can be improved in addition xylitol, steviol glycoside in lozenge, addition vitamin, glucose zinc can replenishing vitamins.
Description
Technical field
It is extracted the invention belongs to drug and preparation field is specifically the extraction resveratrol system from Grape Skin
The method of standby resveratrol lozenge.
Background technique
Resveratrol is a kind of natural activity composition, and scientists conduct extensive research its natural resources, arrives mesh
Before until, at least 21 sections, 31 category 72 kinds of plants in have found resveratrol, such as: the Vitis of Vitaceae, porcelain ampelopsis
Belong to；Arachis, Cassia, the Sophora of pulse family；Liliaceous Veratrum；The eucalyptus category of ma Yao Jin section；The Polygonum etc. of polygonaceae.In the presence of
Many plants of resveratrol are common medicinal plant, such as Cassia, black false hellebore, polygonum cuspidate；Some is exactly food, such as: grape.It
Right resveratrol can also distribution and biosynthesis in plant in the form of glucoside.In all floristics of nature, polygonum cuspidate
Resveratrol content be highest, up to 100~200 μ g/g, if in polygonum cuspidate in the form of glucoside existing for resveratrol also calculate
Inside, content will be up to 700 μ g/g.In addition to this, Resveratrol content occupies second place in Grape Skin.
Resveratrol is the stronger polyphenol compound of activity, is a kind of important phytoalexin, to inhibit cancer cell,
Reduce blood lipid, prevention and cure of cardiovascular disease, it is anti-oxidant, delay senescence the effects of it is obvious, be called after taxol again
One new green anticancer drug.Resveratrol is mainly extracted from the plants such as polygonum cuspidate, Grape Skin and is obtained, function, safety, green,
Environmental protection is the natural plant extract for representing future thrust.Modern medicine study shows: proving that resveratrol has human body
There are many good pharmacological action and health-care effects.Therefore, in recent years, influence of the resveratrol to bodily fuctions is increasingly subject to weight
Depending on.As food additives, molecular structure is clear, and it is one of typical third generation healthy food material that the mechanism of action, which understands,
European and American countries are developed into health food and are listed, and dosage form has tablet, capsule, oral solution；It is anti-oxidant using its, delay to decline
Old effect is obvious.
The general extraction methods of resveratrol have solvent extraction method, enzymatic isolation method at present.Solvent extraction method, enzymatic isolation method time-consuming compared with
Long, recovery rate is low.Due to being influenced by resveratrol concentration in resveratrol extract is lower, so that contain in each tablet
Resveratrol is lower, and user needs the tablet of edible 4-5 piece to can be only achieved specified volume daily.
Summary of the invention
Object of the present invention is to be intended to provide a kind of resveratrol lozenge and preparation method thereof, preparation method is simple, the period
Short, Resveratrol content is higher, and to present containing sheet form, mouthfeel color is good.
To realize the above-mentioned technical purpose, The technical solution adopted by the invention is as follows:
A kind of resveratrol process for preparing buccal lozenge, includes the following steps,
The preparation of resveratrol: taking grape skin, is added 60%-80% edible ethanol solution, solid-liquid ratio 1:1-10, then
It carries out microwave digestion twice at 50 °C, extracts 0.05h every time, filtered after impregnating 30min, filtrate twice is merged
After chromatograph, then eluted with the edible ethanol solution of 70%-90%, be spray-dried to obtain white black false hellebore after 60 DEG C of eluent concentrations
Alcohol extracting thing；
(2) it mixes: resveratrol extract, xylitol, steviol glycoside, vitamin, glucose zinc, food starch etc. is pressed
It is uniformly mixed according to ratio；
(3) said mixture tabletting is obtained into resveratrol lozenge；
Wherein, the power of microwave is 300-600W.
Preferably, as the edible ethanol of leaching liquor, its is dense for one kind as a kind of resveratrol process for preparing buccal lozenge of the present invention
Degree is 70%.
Another kind as a kind of resveratrol process for preparing buccal lozenge of the present invention preferably, as eluent edible ethanol its
Concentration is 85%.
Another as a kind of resveratrol process for preparing buccal lozenge of the present invention is preferred, and sheet frame is used after leaching liquor is merged
300 mesh secondary filters, the analysis of filtrate peroxidating aluminium layer.
Another as a kind of resveratrol process for preparing buccal lozenge of the present invention is preferred, in step (3), will be uniformly mixed
Mixture later carries out tabletting and is sealed, and the temperature of tabletting is 20-25 DEG C, and humid control is in 20-30%.
The present invention also provides the formulas of resveratrol lozenge prepared by the above method, by weight percentage include white black false hellebore
Alcohol 40-50%, xylitol 10-15%, steviol glycoside 0.001-0.01%, vitamin 21%, zinc gluconate 4%, edible shallow lake
Powder 10-25%.
Preferably, vitamin specifically includes vitamin B1, B2, B3, B5, B6 each 0.6%, vitamin C 18%.
Microwave radiation frequency electromagnetic waves penetrate Extraction medium, reach the inside vascular bundle and glandular cell's system of Grape Skin.Due to
Microwave energy is absorbed, cell interior temperature rises rapidly, and making its cell interior pressure is more than cell wall expansion ability to bear, and cell is broken
It splits, intracellular effective component freely flows out, and can be captured at a lower temperature by ethyl alcohol.So bold and unrestrained utilize microwave digestion,
The temperature condition of extraction can be reduced, extraction time is shortened, from traditional extraction four hours, shorten to extraction half an hour, simultaneously also
The content that resveratrol in resveratrol extract can be improved enables its content to reach 10%.So that be prepared
The concentration of resveratrol is higher in resveratrol lozenge.And xylitol, steviol glycoside are added in lozenge the present invention, can mention
The mouthfeel of high lozenge.This lozenge can also supplement each biostearin simultaneously.
Specific embodiment
In order to make those skilled in the art that the present invention may be better understood, below with reference to embodiment to the technology of the present invention
Scheme further illustrates.
Embodiment one
A kind of resveratrol lozenge includes resveratrol 50%, xylitol 12%, steviol glycoside by weight percentage
0.005%, vitamin B1, B2, B3, B5, B6 each 0.6%, vitamin C 18%, zinc gluconate 4%, food starch 13%.
The preparation method of the lozenge, includes the following steps,
(1) preparation of resveratrol: taking grape skin 100kg, 5 times of 70% edible ethanol solution is added, solid-liquid ratio 1:
5, microwave digestion is carried out twice under the conditions of 50 DEG C, extracts 0.05h every time, is filtered after impregnating 30min, filtrate will be merged twice
300 mesh secondary filter of sheet frame, the analysis of filtrate peroxidating aluminium layer are used afterwards, then are eluted with 85% edible ethanol solution, eluent 60
DEG C concentration after be spray-dried to obtain resveratrol extract 1.3kg, content 11.2%；
(2) mix: by 50 parts of resveratrol extract, 12 parts of xylitol, 0.005 part of steviol glycoside, vitamin B1, B2,
Each 0.6 part of B3, B5, B6,18 parts of vitamin C, 4 parts of zinc gluconate, 13 parts of food starch be uniformly mixed；
(3) mixture after being uniformly mixed is subjected to tabletting and be sealed, the temperature of tabletting is 20-25 DEG C, humidity
Resveratrol lozenge is made in 20-30% in control.
Wherein, the power of microwave is 400W.
Reach 11.2% using Resveratrol content made from the above method, the concentration of resveratrol in lozenge can be increased,
From each edible 4-5 piece, it is changed to every time 1 edible.And the production cycle is 17h, shortens 7h compared with conventional method.
Embodiment two
A kind of resveratrol lozenge includes resveratrol 45%, xylitol 12%, steviol glycoside by weight percentage
0.1%, vitamin B1, B2, B3, B5, B6 each 0.6%, vitamin C 18%, zinc gluconate 4%, food starch 18%.
The preparation method of the lozenge, includes the following steps,
(1) preparation of resveratrol: taking grape skin 100kg, 10 times of 65% edible ethanol solution is added, solid-liquid ratio 1:
10, microwave digestion is carried out twice under the conditions of 50 DEG C, extracts 0.05h every time, is filtered after impregnating 30min, filtrate will be closed twice
And 300 mesh secondary filter of sheet frame is used afterwards, the analysis of filtrate peroxidating aluminium layer, then eluted with 75% edible ethanol solution, eluent
It is spray-dried to obtain resveratrol extract 1.22kg, content 10.9% after 60 DEG C of concentrations；
(2) mix: by 45 parts of resveratrol extract, 12 parts of xylitol, 0.1 part of steviol glycoside, vitamin B1, B2,
Each 0.6 part of B3, B5, B6,18 parts of vitamin C, 4 parts of zinc gluconate, 18 parts of food starch be uniformly mixed；
(3) mixture after being uniformly mixed is subjected to tabletting and be sealed, the temperature of tabletting is 20-25 DEG C, humidity
Resveratrol lozenge is made in 20-30% in control.
Wherein, the power of microwave is 500W.
A kind of resveratrol lozenge provided by the invention and preparation method thereof is described in detail above.Specific implementation
The explanation of example is merely used to help understand method and its core concept of the invention.It should be pointed out that for the general of the art
, without departing from the principle of the present invention, can be with several improvements and modifications are made to the present invention for logical technical staff, this
A little improvement and modification are also fallen within the protection scope of the claims of the present invention.
Claims (6)
1. a kind of resveratrol process for preparing buccal lozenge, it is characterised in that: include the following steps,
(1) preparation of resveratrol: taking grape skin, is added 60%-80% edible ethanol solution, solid-liquid ratio 1:1-10, then
It carries out microwave digestion twice at 50 °C, extracts 0.05h every time, filtered after impregnating 30min, after filtrate twice is merged
Chromatography, then eluted with the edible ethanol solution of 70%-90%, it is spray-dried to obtain resveratrol after 60 DEG C of eluent concentrations
Extract；
(2) it mixes: proportionally by resveratrol extract, xylitol, steviol glycoside, vitamin, glucose zinc, food starch
It is uniformly mixed；
(3) said mixture tabletting is obtained into resveratrol lozenge.
2. a kind of resveratrol process for preparing buccal lozenge according to claim 1, it is characterised in that: as the edible of leaching liquor
Its concentration of ethyl alcohol is 70%.
3. a kind of resveratrol process for preparing buccal lozenge according to claim 1, it is characterised in that: as the edible of eluent
Its concentration of ethyl alcohol is 85%.
4. a kind of resveratrol process for preparing buccal lozenge according to claim 1, it is characterised in that: adopted after merging leaching liquor
With 300 mesh secondary filter of sheet frame, the analysis of filtrate peroxidating aluminium layer.
5. a kind of resveratrol process for preparing buccal lozenge according to claim 1, it is characterised in that: in step (3), will mix
Mixture after closing uniformly carries out tabletting and is sealed, and the temperature of tabletting is 20-25 DEG C, and humid control is in 20-30%.
6. resveratrol lozenge made from method according to claim 1-5, it is characterised in that: percentage by weight
Than including resveratrol 40-50%, xylitol 10-15%, steviol glycoside 0.001-0.01%, vitamin 21%, gluconic acid
Zinc 4%, food starch 10-25%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811548829.XA CN109432243A (en) | 2018-12-18 | 2018-12-18 | A kind of resveratrol process for preparing buccal lozenge |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811548829.XA CN109432243A (en) | 2018-12-18 | 2018-12-18 | A kind of resveratrol process for preparing buccal lozenge |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109432243A true CN109432243A (en) | 2019-03-08 |
Family
ID=65559340
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811548829.XA Pending CN109432243A (en) | 2018-12-18 | 2018-12-18 | A kind of resveratrol process for preparing buccal lozenge |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109432243A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111359255A (en) * | 2020-03-31 | 2020-07-03 | 山东博奥克生物科技有限公司 | Resveratrol tablet and processing production equipment thereof |
| CN112586738A (en) * | 2020-12-15 | 2021-04-02 | 吉首大学 | Pueraria flavone buccal tablet and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101338327A (en) * | 2008-08-13 | 2009-01-07 | 长沙华诚生物科技有限公司 | Process for extracting resveratrol with purity higher than 98 0.000000rom giant knotweed |
| CN103622925A (en) * | 2012-08-30 | 2014-03-12 | 山东博奥克生物科技有限公司 | Resveratrol tablet and preparation method therefor |
-
2018
- 2018-12-18 CN CN201811548829.XA patent/CN109432243A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101338327A (en) * | 2008-08-13 | 2009-01-07 | 长沙华诚生物科技有限公司 | Process for extracting resveratrol with purity higher than 98 0.000000rom giant knotweed |
| CN103622925A (en) * | 2012-08-30 | 2014-03-12 | 山东博奥克生物科技有限公司 | Resveratrol tablet and preparation method therefor |
Non-Patent Citations (1)
| Title |
|---|
| 缪文玉，等: "微波辅助提取葡萄皮渣中白藜芦醇的工艺研究", 《食品安全质量检测学报》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111359255A (en) * | 2020-03-31 | 2020-07-03 | 山东博奥克生物科技有限公司 | Resveratrol tablet and processing production equipment thereof |
| CN111359255B (en) * | 2020-03-31 | 2021-12-21 | 山东博奥克生物科技有限公司 | Resveratrol tablet and processing production equipment thereof |
| CN112586738A (en) * | 2020-12-15 | 2021-04-02 | 吉首大学 | Pueraria flavone buccal tablet and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Salahuddin et al. | Phenolic profiling and evaluation of in vitro antioxidant, α-glucosidase and α-amylase inhibitory activities of Lepisanthes fruticosa (Roxb) Leenh fruit extracts | |
| Zhu et al. | Determination of anti-hyperglycaemic activity in steroidal glycoside rich fraction of lily bulbs and characterization of the chemical profiles by LC-Q-TOF-MS/MS | |
| Zheng et al. | Research advances in lotus leaf as Chinese dietary herbal medicine | |
| JP6170674B2 (en) | Method for producing fermented ginseng concentrate or powder | |
| CN109432243A (en) | A kind of resveratrol process for preparing buccal lozenge | |
| CN101766690A (en) | Multipurpose utilization method for improving the value of schisandra chinensis medicinal material | |
| CN104523479B (en) | Application and whitening articles for use of the himalayan prinsepia leaf extract in whitening articles for use | |
| Patwekar et al. | In vitro inhibitory effect on alpha amylase enzyme by polyherbal dip tea in diabetes | |
| Pramono et al. | Effect of herbal combination of Andrographis paniculata (Burm. f) Ness and Gynura procumbens (Lour.) Merr ethanolic extracts in alloxan-induced hyperglycemic rats. | |
| KR101963046B1 (en) | Composition of processed ginseng having increased ginsenoside compound K, chlorgenic acid and quercetin, and preparation method thereof | |
| CN105640971B (en) | Application of the total saposins in terms of preparing auxiliary hyperglycemic drug in prematurity Fructus Monordicae extract | |
| CN103497091B (en) | Compound with tyrosinase inhibitory activity and preparation method thereof | |
| CN103393574A (en) | Fruit extract mixture and application thereof | |
| CN114081178B (en) | Rosa roxburghii pomace combined phenol with remarkable antioxidant activity and preparation method and application thereof | |
| KR100706111B1 (en) | A ginseng preparation using vitamin c and process for thereof | |
| CN111700927B (en) | Medicinal and edible composition with blood sugar reducing effect and preparation method and application thereof | |
| CN103800384B (en) | Cordyceps cicadae Shing active site and preparing the application in neuroprotective and antiaging agent | |
| KR20120126985A (en) | Method to increase the concentration of components on ginseng prosapogenins using microwave against the aerial part of ginseng | |
| KR20140003705A (en) | Method for manufacturing red ginseng extract with enhanced function and the extact thereof | |
| CN109276637B (en) | Semen allii tuberosi extract, preparation method thereof and application thereof in preparing liver-protecting medicine | |
| CN105497413A (en) | Chinese yam overground part extract and preparing method and application thereof | |
| KR101622555B1 (en) | Composition for preventing or decreasing hair loss | |
| KR20200132439A (en) | Method for Manufacturing Fermented Ginseng Tablet | |
| CN103768116A (en) | GMP (Good Manufacturing Practice) production technology and application method of pseudo-ginseng powder bag-steeping-type products | |
| CN103626811B (en) | A kind of method of extraction and isolation phlorizin from cynomorium songaricum |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190308 |